| Name | Title | Contact Details |
|---|
Celtaxsys is a privately-held clinical stage drug discovery and development company with operations in San Francisco, CA and Atlanta, GA.
Diagenode is a leading global provider of complete solutions for epigenetics research, biological sample preparation, and diagnostics assays based in Liege, Belgium and NJ, USA. The company has developed a comprehensive approach to gain new insights into epigenetics studies. The company offers innovative Bioruptor® shearing and IP-Star® automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. The company`s latest innovations include a unique, full automation system, the industry`s most validated antibodies, the Megaruptor shearing system for long fragment generation in sequencing, and epigenetics assay services.
HealthTell is committed to empowering the next generation of diagnostics and therapeutics for complex immune-mediated diseases such as cancer, autoimmune disorders, and infectious diseases. Based on robust proprietary technology, HealthTell is developing the first and only diagnostic platform capable of assessing an individual`s immune system response to specific diseases. Applicable to a broad range of therapeutic areas, HealthTell is empowering physicians and patients to proactively manage health and make more informed decisions.
At Cornerstone BioPharma, we are constantly striving to make good medicines better. We know that Healthcare providers and patients are concerned about the safety of today's medications-that makes tried and true medications very appealing. However, due to
eFFECTOR Therapeutics is pioneering the discovery and development of translation regulators as a new class of small molecule therapeutics for cancer. The company`s investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving healthy physiological processes. eFFECTOR`s most advanced program focuses on the development of eFT508, a highly selective MNK1 and MNK2 inhibitor. MNK1 and 2 are kinases acting as signal integrators at the convergence of multiple oncogenic pathways to regulate production of disease-driving proteins. The company has additional translation regulation programs currently in discovery. eFFECTOR has raised $55M in Series A financing from top-tier private and corporate venture funds, including U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One and The Column Group.